Dermatological manifestations of COVID 19
DOI:
https://doi.org/10.66344/jpad.v31i3.1863Abstract
Introduction COVID 19 (SARS 2 virus) was first isolated in China in December 2019 from the specimen of patients presented with lower respiratory tract infection. It was declared a global pandemic on March 11, 2020. Coronavirus disease 2019 infected patients can presents with different dermatological manifestations even in some cases; the dermatological manifestation may be the only presenting complaints of the patients.
Objective To find dermatological manifestations in patients infected with COVID 19 virus.
Methods After getting ethical approval from the hospital ethical and research committee, all the tested positive for SARS 2 virus were included in the study. Strict precautionary measures were taken according to the WHO guidelines. Patients having any chronic dermatological disease in the past or having more than two weeks duration of any dermatological illness were excluded. Photographs were taken from the patients having any dermatological manifestations. These photographs were then shared with the consultant dermatologists of the unit by hiding the course of clinical illness of the patients. The expert opinion of the consultant was considered as the final one.
Results Mean age was 41,53 years±1.6008E1 (3 months to 85 years) with 160 males (65.6%) and 84 females (34.4%). Pseudo chilblains, maculopapular rash, vesicular rash, and urticarial rash were noted in 13.9%, 15.6%, 4.9%, and 7%, respectively. Oral cavity erythema, ulcers, and erosions were noted in 25%, 11.9%, and 14.3% of patients. Based on gender, the p-value was significant for maculopapular rash (p=0.02) and oral petechiae (p=0.04), while based on age, the p-value was significant for urticarial rash (p=0.01) and vesicular rash (p=0.03).
Conclusion COVID 19 is a severe form of viral illness with a fatal outcome. Dermatological manifestations may sometimes be the sole presenting complaints of the patients.
References
1. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19-studies needed. N Eng J Med.2020;382(13):1194-6.
2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 among children in China. Pediatrics.2020;145(6):e20200702.
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun.2020;109:102433.
4. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis.2020;34:101623.
5. World health organization report on Covid 19. World health Organ, July 01, 2020.
6. Rana W, Mukhtar S, Mukhtar S. Mental health of medical workers in Pakistan during the pandemic COVID-19 outbreak. Asian J Psychiatr.2020;51:102080.
7. Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol.2020;34(5):e212-e213.
8. Galván Casas C, Catala AC, Carretero Hernández G, Rodríguez‐Jiménez P, Fernández‐Nieto D, Rodríguez‐Villa Lario A et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol.2020;183(1):71-7
9. Tammaro AN, Adebanjo GA, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID‐19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol.2020;34(7):e306-e307.
10. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol.2020;83(2):700.
11. Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID‐19: a french observational study. J Eur Acad Dermatol Venereol.2020;34(9):e451-e452.
12. Fernandez‐Nieto D, Ortega‐Quijano D, Segurado‐Miravalles G, Pindado‐Ortega C, Prieto‐Barrios M, Jimenez‐Cauhe J. Comment on: Cutaneous manifestations in COVID‐19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol. 2020;34(6):e252-e254.
13. Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A, Provero MC. Acral cutaneous lesions in the time of COVID‐19. J Eur Acad Dermatol Venereol. 2020;34(8):e346-e347.
14. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID‐19 infection. J Eur Acad Dermatol Venereol.2020;34(6):e244-e245.
15. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave‐Roblot F, Masson Regnault M. Comment on “Cutaneous manifestations in COVID‐19: a first perspective” by Recalcati S. Eur Acad Dermatol Venereol.2020; 34(7):e299-e300.
16. de Masson A, Bouaziz JD, Sulimovic L, Cassius C, Jachiet M, Ionescu MA et al. Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. J Am Acad Dermatol.2020;83(2):667-70
17. Galvan Casas C, Catala A, Carretero Hernandez G, et al.Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol.2020;183(1):71-7.
18. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T.Chilblain-like lesions on feet and hands during the COVID-19 pandemic. Int J Dermatol.2020;59:739-43.
19. Marzano AV, Genovese G, Fabbrocini G et al. varicella like exanthem as a specific COVID 19 associated skin manisfestation. Multicenter case seriesof 22 patients. J Am Acad Dermatol.2020;83(1):280-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Dawood Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
